Lessons from the ABSORB everolimus-eluting bioresorbable vascular scaffold programme
P. Serruys offers an overview and evaluation of the past, ongoing and upcoming clinical trials regarding the Absorb everolimus-eluting bioresorbable vascular scaffold (BRS). Were the concerns generated by earlier trials justified? What impact has this had on the current ABSORB III trial, and has this trial provided us with the results we expected after 1 or 2 years from this device? What will new iterations of this device have to offer? Understand the essential BVS message from a recognised expert …
This interview was recorded at the American College of Cardiology Scientific Sessions 2017 (ACC.17).